April Schultz

Dr. April Schultz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
SCSavannah Collett
Savannah Collett
AMAmanda Massmann
Amanda Massmann
NPNatasha J. Petry
Natasha J. Petry
JHJoel Van Heukelom
Joel Van Heukelom
ASApril Schultz
April Schultz
JBJordan Baye
Jordan Baye
Metoprolol is a medication commonly utilized in select patients to achieve a reduction in heart rate, systolic blood pressure, or other indications. A majority of metoprolol metabolism occurs via CYP2D6. Decreased expression of the CYP2D6 enzyme increases the concentration of metoprolol. Current pharmacogenomics guidelines by the Dutch Pharmacogenomics Working Group recommend slower titrations and dose decreases to minimize adverse effects from poor metabolizers or normal metabolizers taking concomitant medications that are strong inhibitors of CYP2D6 (phenoconverters). This study aimed to evaluate adverse effects such as bradycardia, hypotension, and syncope in patients who are expected to have absent CYP2D6 enzyme activity due to drug–drug or drug–gene interactions. The secondary aims of this study were to evaluate heart rate measurements for the included participants. Retrospective data were collected for individuals with CYP2D6 genotyping results obtained for clinical purposes. Three categories (CYP2D6 normal metabolizers, poor metabolizers, and phenoconverters) were assigned. A total of 325 participants were included. There was no statistically significant difference found in the primary composite outcome between the three metabolizer groups (p = 0.054). However, a statistically significant difference was identified in the incidences of bradycardia between the poor metabolizers and the normal metabolizers or phenoconverters (p < 0.0001). The average heart rates were 2.8 beats per minute (bpm) and 2.6 bpm lower for the poor metabolizer and phenoconverter groups, respectively, compared to the normal metabolizers (p < 0.0001 for both comparisons). This study further supports the role of genetic testing in precision medicine to help individualize patient care as CYP2D6 poor metabolizers taking metoprolol were found to have an increase in bradycardia. Additional research is needed to clarify the dose relationship in this drug–gene interaction.

17 July 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
CPCharlene L Preys
Charlene L Preys
CZCarrie L Blout Zawatsky
Carrie L Blout Zawatsky
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
RGRobert C Green
Robert C Green
KCKurt Christensen
Kurt Christensen
Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx testing and its perceived util...

29 February 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
AMAmanda Massmann
Amanda Massmann
KCKurt Christensen
Kurt Christensen
JHJoel Van Heukelom
Joel Van Heukelom
ASApril Schultz
April Schultz
MSMuhammad Hamza Saad Shaukat
Muhammad Hamza Saad Shaukat
TSTomasz P. Stys
Tomasz P. Stys

12 June 2024 in Pharmacogenomics
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
MWMax Weaver
Max Weaver
ASApril Schultz
April Schultz
DFDebbie M Figueroa
Debbie M Figueroa
KCKurt Christensen
Kurt Christensen
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.

30 July 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RSRachael M. Stone
Rachael M. Stone
GHGlenda Hoffecker
Glenda Hoffecker
ASApril Schultz
April Schultz
BDBrittney H. Davis
Brittney H. Davis
SBSalma A. Bargal
Salma A. Bargal
CLCraig R. Lee
Craig R. Lee
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles. While CYP2C19 ‐guided DAPT is well‐established for some cardiovascular indications, its use in neurovascular settings has remained limited until recently. This study characterized current implementation strategies for CYP2C19 ‐guided DAPT for neurovascular indications across institutions in the Pharmacogenomics Global Research Network Implementation Working Group. A REDCap survey was distributed to 54 institutions targeting those currently utilizing or planning to implement CYP2C19 testing to guide clopidogrel use for neurovascular indications. The survey collected data on implementation status, workflows, testing logistics, clinical decision support (CDS), and guideline concordance. Fifteen institutions met inclusion criteria; 80% were in the United States and 87% were academic centers. CYP2C19 testing was used for neurovascular indications at 12 sites, most commonly for AIS, intracranial aneurysm repair, and intracranial stenting. Implementation was often built on infrastructure previously established for cardiovascular indications. Most sites used multigene panels, offered testing in both inpatient and outpatient settings, and returned results within 7 days. Eighty percent of sites provided CDS to support application of results. All sites recommended an alternative P2Y12 inhibitor (e.g., ticagrelor) for poor metabolizers, and most did for intermediate metabolizers. CYP2C19 ‐guided antiplatelet therapy for neurovascular indications is expanding, with many implementations leveraging preexisting infrastructure from cardiovascular settings. Broader adoption and outcome‐focused research are needed to optimize the clinical utility of genotype‐guided DAPT in neurovascular care.

2 July 2026 in JAPhA Practice Innovations
Verified
Journal Article
Open access
ASApril Schultz
April Schultz
DGDavid Gregornik
David Gregornik
JNJenny Q. Nguyen
Jenny Q. Nguyen